(Finance) – TheBiopharmaceutical company that develops drugs for the treatment of cancer and chronic inflammatory diseasescommunicated the dates for public disclosure of the economic – financial results which will be examined by the Board of Directors and the Shareholders’ Meeting during 2024.
Wednesday 03/27/2024
Board of Directors: Approval of the Draft Financial Statement and the 2023 Consolidated Financial Statements
Monday 04/29/2024
Assembly: Approval of the 2023 Financial Statements
Tuesday 05/07/2024
Board of Directors: Approval of the press release containing quarterly information with selected information indicative of the performance of the activity relating to the first quarter of 2024 (net financial position and progress of the main trials of NidlegyTM and Fibromun)
Wednesday 09/25/2024
Board of Directors: Approval of the Half-Year Financial Report as at 30 June 2024
Thursday 07/11/2024
Board of Directors: Approval of the press release containing quarterly information with selected information indicative of the performance of the activity relating to the third quarter of 2024 (net financial position and progress of the main trials of NidlegyTM and Fibromun)